Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers.
Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers.
复制标题
DOI：
10.3947/ic.2022.0009
复制
发表时间：
2022-03
影响因子：
4.2
通讯作者：
Lee JY
中科院分区：
文献类型：
--
作者：
Lim S;Lee Y;Kim DW;Park WS;Yoon JH;Lee JY
针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体动力学在评估疫苗有效性和持久性、群体免疫力、额外接种以及针对冠状病毒疾病的免疫保护预测模型2019中发挥重要作用。血清采集时间为AZD 1222（AstraZeneca，剑桥，UK）首次接种后4周和8周，以及第2次接种后2周和16周，给药间隔为12周。使用市售的R-FIND SARS-CoV-2中和抗体ELISA试剂盒（SG Medical Inc.，韩国首尔）。还研究了性别、年龄和不良事件对中和抗体滴度的可能影响。Nab滴度（中位抑制%）在达到峰值后不久开始下降。在第1次和第2次接种后8周（49.5% vs. 55.4%，P = 0.021）和16周（40.6% vs. 53.9%，P = 0.006）时，老年组（≥56岁）中的这种下降比年轻组（≤39岁）更明显。8周龄组（r =-0.2091，P = 0.0284）和28周龄组（r =-0.2811，P = 0.0029）Nab滴度与年龄呈负相关。第1针和第2针Nab阳转率分别为89.1%和100%。16周后，100%的血清阳性率急剧下降至74.5%。与未发生不良事件的受试者（51.8%）相比，发生1起或多起全身性不良事件（74.2%，P = 0.0203）或发生1起或多起局部和全身性不良事件（77.1%，P = 0.0003）的受试者的中位抑制率较高。AZD 1222（AstraZeneca，UK）疫苗接种诱导的Nab在生产期后不久开始降解。在降解期间，老年组的Nab滴度低于年轻组。这似乎是因为Nab的降解过程在老年人中更为明显。这可能解释了为什么老年人的突破性感染频率、疾病严重程度和死亡率较高，可能需要重新接种疫苗以确保强大的免疫力。
The kinetics of neutralizing antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) play an important role in evaluating vaccine efficacy and durability, herd immunity, additional vaccination, and prediction models of immune protection against coronavirus disease 2019. Serum collection times were 4 and 8 weeks after 1st inoculation of AZD1222 (AstraZeneca, Cambridge, UK), and 2 and 16 weeks after 2nd inoculation with 12-week dosing intervals. Neutralizing antibody (Nab) titers were measured indirectly using commercially available R-FIND SARS-CoV-2 Neutralizing Antibody ELISA Kit (SG Medical Inc., Seoul, Korea). Possible influences of gender, age, and adverse events on neutralizing antibody titer were also investigated. Nab titers (median inhibition %) started to decrease shortly after reaching peaks. This decrease was more pronounced in the elderly group (≥56 years) than in the young group (≤39 years) at 8 weeks (49.5% vs. 55.4%, P = 0.021) and 16 weeks (40.6% vs. 53.9%, P = 0.006) after the 1st and 2nd inoculation. And Nab titers were inversely correlated with age in the 8-week (r = -0.2091, P = 0.0284) and the 28-week group (r = -0.2811, P = 0.0029). Seropositive conversion of Nab reached 89.1% and 100% following 1st and 2nd inoculation. This 100% seropositivity was dropped sharply to 74.5% after 16 weeks. Compared to subjects without adverse events (51.8%), median inhibition was higher in subjects with one or more systemic adverse events (74.2%, P = 0.0203) or those with one or more local and systemic adverse events (77.1%, P = 0.0003). Nab induced by AZD1222 (AstraZeneca, UK) vaccination started to degrade shortly after the production period. Nab titers were lower in the elderly than in younger group during the degradation period. This seems to be because the degradation process of Nab is more pronounced in the elderly. This may explain why the frequency of breakthrough infections, disease severity, and mortality were higher in the elderly and may require revaccination to ensure robust immunity.